Definition and epidemiology
Kaposi's sarcoma is a low-grade vascular neoplasm arising from lymphatic endothelial cells, driven by infection with human herpesvirus 8 (HHV-8, also called KS-associated herpesvirus, KSHV). It is classified into four overlapping epidemiologic forms:
- Classic (sporadic) KS — older men of Mediterranean, Eastern European, or Middle Eastern descent; indolent course
- Endemic (African) KS — seen in sub-Saharan Africa, affects younger adults and children, independent of HIV; often more aggressive
- Iatrogenic (transplant-associated) KS — occurs in solid organ transplant recipients on immunosuppressive therapy
- Epidemic (AIDS-associated) KS — the most common form worldwide, occurs in HIV-infected patients with advanced immunosuppression; this is the form most tested on exams
HHV-8 seroprevalence is high in sub-Saharan Africa and parts of the Mediterranean, lower in North America and Northern Europe. KS incidence fell sharply after the introduction of combination antiretroviral therapy (ART), but it remains the most common HIV-associated malignancy worldwide, particularly in regions with limited ART access.
- Kaposi's sarcoma is essentially always HHV-8 (KSHV) positive — look for LANA-1 on immunohistochemistry.
- Epidemic (AIDS-associated) KS is the most commonly tested form and the most common HIV-associated cancer.
- First-line treatment in HIV-positive patients is starting or optimizing antiretroviral therapy, not jumping straight to chemotherapy.
- Biopsy shows spindle cells, slit-like vascular spaces, and extravasated RBCs with hemosiderin.
- Hard palate is a classic oral site for KS lesions.
- Liposomal doxorubicin is the typical first-line systemic chemotherapy for advanced/visceral disease.
- Pulmonary KS has the highest mortality among visceral forms.
- In transplant patients, switching immunosuppression to an mTOR inhibitor (sirolimus) can help treat iatrogenic KS.
Etiology and risk factors
HHV-8 infection is necessary but not sufficient; tumor development requires a permissive, immunosuppressed environment.
- HHV-8 (KSHV) infection — a gammaherpesvirus transmitted via saliva, sexual contact, and vertically; infects endothelial cells and drives proliferation through viral oncoproteins (e.g., LANA, vGPCR)
- HIV/AIDS with low CD4 count — the dominant risk factor for epidemic KS; risk rises sharply as CD4 count falls, especially below 200 cells/microL
- Iatrogenic immunosuppression — transplant recipients on calcineurin inhibitors or other immunosuppressants
- Male sex — classic and epidemic KS are far more common in men
- Geographic/ethnic background — higher HHV-8 seroprevalence in Mediterranean and sub-Saharan African populations
Pathophysiology
HHV-8 infects lymphatic endothelial cells and spindle-shaped tumor cells, inducing a latent infection with occasional lytic reactivation. Viral proteins (including latency-associated nuclear antigen and viral G-protein-coupled receptor) dysregulate cell cycle control, inhibit apoptosis, and stimulate angiogenesis and lymphangiogenesis through pathways such as VEGF signaling.
The result is a proliferation of spindle-shaped endothelial-derived cells forming slit-like vascular spaces filled with red blood cells, accompanied by extravasated erythrocytes, hemosiderin deposition, and a mixed inflammatory infiltrate. This explains the characteristic violaceous (purple-brown) color of lesions. Immunosuppression (from HIV or iatrogenic causes) impairs HHV-8-specific T-cell immunity, allowing unchecked viral-driven proliferation; restoring immune function (via ART or reducing immunosuppressants) can lead to tumor regression, underscoring the central pathogenic role of immune control rather than viral infection alone.
Clinical features
Lesions are classically painless, violaceous (purple-brown to red) macules, papules, plaques, or nodules that do not blanch with pressure.
- Skin — most common site; lesions on the face (especially nose), trunk, legs, and genitalia; can follow skin tension lines
- Oral mucosa — hard palate is a classic location
- Lymph nodes — lymphadenopathy with or without lymphedema, especially in endemic/African form
- GI tract — can be asymptomatic or cause bleeding, obstruction, or protein-losing enteropathy; often found incidentally on endoscopy
- Lungs — pulmonary KS can cause dyspnea, cough, hemoptysis, and pleural effusion; a feared complication with significant mortality
Lesions may be few and indolent (classic KS) or widespread and rapidly progressive with visceral involvement (epidemic/endemic KS in advanced immunosuppression).
Diagnosis
Diagnosis requires histopathologic confirmation; clinical appearance alone is not sufficient.
- Skin/mucosal biopsy — shows spindle cell proliferation, slit-like vascular spaces, extravasated red blood cells, and hemosiderin-laden macrophages
- Immunohistochemistry — tumor cells stain positive for HHV-8 latent nuclear antigen (LANA-1); also express endothelial markers (CD31, CD34)
- HIV testing — all patients with suspected KS should be tested for HIV if status is unknown
- CD4 count and HIV viral load — to stage immunosuppression and guide ART decisions
- Staging workup — chest imaging and consideration of endoscopy/bronchoscopy if visceral involvement suspected (dyspnea, GI bleeding, unexplained anemia)
- AIDS Clinical Trials Group (ACTG) staging system — classifies KS by tumor extent (T), immune status (I, CD4-based), and systemic illness (S) to guide prognosis and treatment
Differential diagnosis
| Condition | Distinguishing feature |
|---|---|
| Bacillary angiomatosis | Bartonella infection; biopsy shows bacilli, not HHV-8; responds to antibiotics |
| Pyogenic granuloma | Solitary, rapidly growing, friable vascular papule; no HHV-8 |
| Angiosarcoma | True malignant vascular tumor; HHV-8 negative; more aggressive |
| Hemangioma | Benign vascular proliferation; typically presents in childhood |
| Dermatofibroma/melanoma | Pigmented lesion but lacks vascular histology and HHV-8 positivity |
| Stasis dermatitis/ecchymosis | Can mimic early KS clinically but biopsy is unremarkable for tumor |
Management
Treatment depends on the clinical form, extent of disease, and immune status; approach is broadly consistent across WHO and major society guidelines, though specific chemotherapy protocols may vary by region.
HIV-associated (epidemic) KS
- Antiretroviral therapy (ART) is first-line and essential in all patients; immune reconstitution alone can cause regression of limited disease
- Localized/limited disease — ART alone may suffice; local therapies (surgical excision, cryotherapy, intralesional chemotherapy, or radiation) for cosmetically troubling or symptomatic lesions
- Advanced, disseminated, or visceral disease — systemic chemotherapy added to ART; liposomal doxorubicin is commonly used first-line systemic chemotherapy; paclitaxel is an alternative, particularly after doxorubicin failure
Classic KS
- Often indolent; observation or local therapy (surgery, radiation, cryotherapy) may be sufficient; chemotherapy reserved for extensive disease
Iatrogenic (transplant-associated) KS
- Reduce or modify immunosuppressive regimen (switching to an mTOR inhibitor such as sirolimus has both immunosuppressive and antitumor/antiangiogenic effects)
- Chemotherapy for extensive or refractory disease
Endemic (African) KS
- Management mirrors epidemic KS when HIV coinfection present; chemotherapy and supportive/palliative care are important given often more aggressive course and limited resources in endemic regions
Complications and prognosis
- Pulmonary KS carries the worst prognosis among organ involvement, with risk of respiratory failure and significant mortality
- GI involvement can cause chronic bleeding, anemia, obstruction, or malabsorption
- Lymphedema from lymphatic obstruction, particularly disfiguring in endemic KS
- Immune reconstitution inflammatory syndrome (IRIS) — paradoxical worsening of KS lesions shortly after starting ART due to recovering immune response; usually managed by continuing ART while treating the flare
- Prognosis is generally favorable for localized classic KS and for epidemic KS responding to ART, with many lesions regressing significantly after immune reconstitution; prognosis is worse with high tumor burden, poor immune status (low CD4), systemic symptoms, and visceral/pulmonary involvement, as reflected in ACTG staging
Think 'HHV-8 = Human Herpesvirus causing Hemorrhagic Vascular tumor in the 8 (immunosuppressed): AIDS, Africa (endemic), Allograft (iatrogenic), and Aged men (classic).'
Practice questions
1. A 34-year-old man with HIV infection and a CD4 count of 85 cells/microL presents with multiple violaceous, non-blanching papules on his trunk and legs, and a lesion on the hard palate. Biopsy of a skin lesion shows spindle cell proliferation with slit-like vascular spaces. Which of the following is the most appropriate initial step in management?
2. A 68-year-old man of Mediterranean descent, HIV-negative and otherwise healthy, presents with a few scattered purple-brown plaques on his lower legs that have been slowly enlarging over two years. Biopsy confirms Kaposi's sarcoma with HHV-8 positivity. Which form of Kaposi's sarcoma does this presentation most likely represent?
3. A 45-year-old renal transplant recipient on tacrolimus and mycophenolate develops multiple violaceous skin nodules. Biopsy confirms Kaposi's sarcoma. Which of the following changes to his immunosuppressive regimen is most likely to help treat the KS in addition to maintaining graft function?
Frequently asked questions
What causes Kaposi's sarcoma?
Kaposi's sarcoma is caused by infection with human herpesvirus 8 (HHV-8), also known as KS-associated herpesvirus. HHV-8 infects lymphatic endothelial cells and drives their abnormal proliferation into vascular tumors. However, the virus alone is usually not enough to cause disease; it typically requires an immunosuppressed state, such as advanced HIV/AIDS, organ transplantation with immunosuppressive therapy, or older age in genetically predisposed populations, to allow the tumor to develop and progress.
What are the first symptoms of Kaposi's sarcoma?
The first symptoms are usually painless, flat or slightly raised purple-brown to red skin lesions, often on the face, legs, trunk, or genitals, that do not blanch when pressed. Oral lesions, especially on the hard palate, are also common early findings. In more advanced or visceral disease, patients may develop lymph node swelling, leg swelling from lymphedema, or symptoms from lung or gastrointestinal involvement such as cough, shortness of breath, or GI bleeding.
How is Kaposi's sarcoma diagnosed?
Kaposi's sarcoma is diagnosed with a biopsy of a suspicious skin or mucosal lesion, which shows characteristic spindle-shaped cells, slit-like vascular spaces, and immunohistochemical staining positive for HHV-8 (LANA-1). All patients should also be tested for HIV if status is unknown, since most cases occur in HIV-positive individuals. Additional imaging or endoscopy may be done if there is concern for lung or gastrointestinal involvement.
Is Kaposi's sarcoma curable?
Kaposi's sarcoma is not always 'curable' in the traditional sense, but it is often very treatable, and lesions can regress completely, especially in HIV-associated cases once antiretroviral therapy restores immune function. Classic (non-HIV) KS is often indolent and manageable long-term with local therapy. Advanced or visceral disease requires chemotherapy and carries a more guarded prognosis, particularly with pulmonary involvement.
Kaposi's sarcoma vs bacillary angiomatosis — what is the difference?
Both cause reddish-purple vascular skin lesions in immunosuppressed patients, but they have entirely different causes and treatments. Kaposi's sarcoma is a tumor caused by HHV-8 infection and diagnosed by biopsy showing spindle cells and HHV-8 positivity, while bacillary angiomatosis is a bacterial infection caused by Bartonella species, diagnosed by biopsy showing bacillary organisms (often with Warthin-Starry stain), and it is curable with antibiotics rather than chemotherapy or ART alone.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: C46
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.